Next Article in Journal
Macrophage-Derived Inflammation Induces a Transcriptome Makeover in Mesenchymal Stromal Cells Enhancing Their Potential for Tissue Repair
Next Article in Special Issue
Screening of Yeast Display Libraries of Enzymatically Treated Peptides to Discover Macrocyclic Peptide Ligands
Previous Article in Journal
Titanium Dioxide Presents a Different Profile in Dextran Sodium Sulphate-Induced Experimental Colitis in Mice Lacking the IBD Risk Gene Ptpn2 in Myeloid Cells
 
 
Review

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer

1
School of Pharmaceutical and Toxicological Sciences and School of Clinical Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA
2
Independent Researcher, Wharton, NJ 07885, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(2), 779; https://doi.org/10.3390/ijms22020779
Received: 4 December 2020 / Revised: 7 January 2021 / Accepted: 10 January 2021 / Published: 14 January 2021
(This article belongs to the Special Issue Molecular Recognition in Protein and Peptide Nanotechnology)
Breast cancer is one of the leading causes of death in women. With improvements in early-stage diagnosis and targeted therapies, there has been an improvement in the overall survival rate in breast cancer over the past decade. Despite the development of targeted therapies, tyrosine kinase inhibitors, as well as monoclonal antibodies and their toxin conjugates, all metastatic tumors develop resistance, and nearly one-third of HER2+ breast cancer patients develop resistance to all these therapies. Although antibody therapy has shown promising results in breast cancer patients, passive immunotherapy approaches have limitations and need continuous administration over a long period. Vaccine therapy introduces antigens that act on cancer cells causing prolonged activation of the immune system. In particular, cancer relapse could be avoided due to the presence of a longer period of immunological memory with an effective vaccine that can protect against various tumor antigens. Cancer vaccines are broadly classified as preventive and therapeutic. Preventive vaccines are used to ward off any future infections and therapeutic vaccines are used to treat a person with active disease. In this article, we provided details about the tumor environment, different types of vaccines, their advantages and disadvantages, and the current status of various vaccine candidates with a focus on vaccines for breast cancer. Current data indicate that therapeutic vaccines themselves have limitations in terms of efficacy and are used in combination with other chemotherapeutic or targeting agents. The majority of breast cancer vaccines are undergoing clinical trials and the next decade will see the fruitfulness of breast cancer vaccine therapy. View Full-Text
Keywords: vaccine; breast cancer; HER2; therapeutic vaccine; cell-based vaccine; DNA-based vaccine vaccine; breast cancer; HER2; therapeutic vaccine; cell-based vaccine; DNA-based vaccine
Show Figures

Graphical abstract

MDPI and ACS Style

Pallerla, S.; Abdul, A.u.R.M.; Comeau, J.; Jois, S. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. Int. J. Mol. Sci. 2021, 22, 779. https://doi.org/10.3390/ijms22020779

AMA Style

Pallerla S, Abdul AuRM, Comeau J, Jois S. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. International Journal of Molecular Sciences. 2021; 22(2):779. https://doi.org/10.3390/ijms22020779

Chicago/Turabian Style

Pallerla, Sandeep, Ata ur Rahman Mohammed Abdul, Jill Comeau, and Seetharama Jois. 2021. "Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer" International Journal of Molecular Sciences 22, no. 2: 779. https://doi.org/10.3390/ijms22020779

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop